OKUR
OnKure Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
OnKure Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
We are a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small-molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
We are a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small-molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for OnKure Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for OnKure Therapeutics, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $18.2M | 11.47% | 0.00% |
| BVF | $14.8M | 9.28% | +63.51% |
| Acorn Capital | $12.9M | 8.14% | 0.00% |
| StepStone | $12.1M | 7.63% | 0.00% |
| ADAR1 | $10.2M | 6.42% | −8.06% |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $18.2M | 11.47% | 0.00% |
| BVF | $14.8M | 9.28% | +63.51% |
| Acorn Capital | $12.9M | 8.14% | 0.00% |
| StepStone | $12.1M | 7.63% | 0.00% |
| ADAR1 | $10.2M | 6.42% | −8.06% |
Expected move
No implied move.
OnKure Therapeutics, Inc.
2.54
−0.05 · −1.75%
—
—